Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells

Journal of Clinical Investigation

Volumn 105, Issue 9, 2000, Pages 1261-1267

  Sullivan, Gregory F ^a   Yang, Jin Ming ^a   Vassil, Andrew ^a   Yang, Jun ^a   Bash Babula, Judy ^a   Hait, William N ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN P53; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL GROWTH; COLONY FORMATION; DRUG ACCUMULATION; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; TEMPERATURE; TEMPERATURE SENSITIVE MUTANT;

EID: 0034063577     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI9290     Document Type: Article

References (27)

1. Sullivan, G., et al. 1998. The expression of drug resistance gene products during the progression of human prostate cancer. Clin. Cancer Res. 4:1393-1403.
2. Wang, Q., and Beck, W.T. 1998. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res. 58:5762-5769.
3. Lowe, S.W., Ruley, H.E., Jacks, T., and Housman, D.E. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:957-967.
4. Zhang, C.C., et al. 1998. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene. 16:1617-1624.
5. Miyashita, T., et al. 1994. Tumor suppressor p53 is a regulator of Bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1799-1805.
6. Chin, K.V., Ueda, K., Pastan, I., and Gottesman, M.M. 1992. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 255:459-462.
7. De Angelis, P., et al. 1995. P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br. J. Cancer. 72:307-311
8. Cole, S.P., and Deeley, R.G. 1998. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays. 20:931-940.
9. Keppler, D., Jedlitschky, G., and Leier, I. 1998. Transport function and substrate specificity of multidrug resistance protein. Methods Enzymol. 292:607-616.
10. Paul, S., Belinsky, M.G., Shen, H., and Kruh, G.D. 1996. Structure and in vitro substrate specificity of the murine multidrug resistance-associated protein. Biochemistry. 35:13647-13655.
11. Hirano, Y., Yamato, K., and Tsuchida, N. 1995. A temperature sensitive mutant of the human p53, Val 138, arrests rat cell growth without induced expression of cip1/waf1/sdi1 after temperature shift-down. Oncogene. 10:1879-1885.
12. Yang, T., et al. 1997. p53 induced by ionizing radiation mediates DNA endjointing activity, but not apoptosis of thyroid cells. Oncogene. 14:1511-1519.
13. Planchon, S.M., et al. 1995. β-Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: ap53-independent response. Cancer Res. 55:3706-3711.
14. Upadhyay, S., et al. 1995. Bcl-2 suppresses expression of p21WAF1/CIP1 in breast epithelial cells. Cancer Res. 55:4520-4524.
15. Murphy, M., Hinman, A., and Levine, A.J. 1996. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev. 10:2971-2980.
16. Kuerbitz, S.J., Plunkett, B.S., Walsh, W.V., and Kastan, M.B. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA. 89:7491-7495.
17. Hukushima, Y., et al. 1999. Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer. Eur. J. Cancer. 35:935-938.
18. Oshika, Y., et al. 1998. Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer. Mod. Pathol. 11:1059-1063.
19. Nguyen, K.T., et al. 1994. Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol. Res. 6:71-77.
20. Murphy, M., et al. 1999. Transcriptional repression by wild-type p53 utilizes histon deacetylases, mediated by interaction with mSin3a. Genes Dev. 13:2490-2501.
21. Leier, I., et al. 1994. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. 269:27807-27810.
22. Leier, I., et al. 1996. ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem. J. 314:433-437.
23. Vanhoefer, U., Yin, M.B., Harstrick, A., Seeber, S., and Rustum, Y.M. 1997. Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N- nitrosourea associated with inhibition of multidrug resistance protein (MRP) function. Biochem. Pharmacol 53:801-809.
24. Lee, W.H., et al. 1994. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA. 91:11733-11737.
25. Esteller, M., et al. 1998. Inactivation of glutathione S-transfcrase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res. 58:4515-4518.
26. Murray, G.I., et al. 1995. The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer. J. Pathol. 177:147-152.
27. O'Brien, P.J., et al. 1996. Chemical carcinogenesis, mutagenesis, and teratogenesis. Can. J. Physiol. Pharmacol. 74:565-571.